Melanoma

ClinicalJuly 27, 2026

Mayo Clinic Trial on CBT for Quality of Life in Stage III-IV Melanoma Patients

A clinical trial is assessing the impact of cognitive behavioral therapy on quality of life for stage III-IV melanoma patients post-treatment.

ClinicalJuly 9, 2026

Study on Cyberknife for Melanoma Brain Metastasis Aims to Improve Treatment Strategies

A clinical trial is underway to evaluate the effectiveness of stereotactic radiosurgery combined with immunotherapy or targeted therapy for melanoma brain metastases.

ClinicalJuly 8, 2026

Case Study: Melanoma Patient with Brain Metastases and DVT Managed with Immunotherapy and Thrombectomy

A 62-year-old melanoma patient with brain metastases and DVT was treated with combination immunotherapy and mechanical thrombectomy.

ClinicalJuly 4, 2026

Study on Vidutolimod and Nivolumab in Melanoma Treatment

The study aims to assess the efficacy of nivolumab alone versus in combination with Vidutolimod (CMP-001) in treating melanoma.

ClinicalJuly 1, 2026

Sex-based differences in TLR agonist efficacy for early-stage melanoma treatment

Intradermal delivery of TLR9 agonist CPG7909 shows sex-based differences in immune response, with men exhibiting superior dendritic cell maturation. TLR7/8 agonist resiquimod shows better activation in female patients.

ClinicalJune 27, 2026

Ipilimumab vs High-Dose Interferon in High-Risk Melanoma Trial

A phase III trial is comparing the efficacy of ipilimumab against high-dose interferon alfa-2b in high-risk stage III-IV melanoma patients post-surgery.

ClinicalJune 25, 2026

Phase III Trial Evaluates Sargramostim and Vaccine Therapy for Melanoma Recurrence Prevention

A phase III trial is underway to compare the efficacy of sargramostim and vaccine therapy alone versus their combination in preventing melanoma recurrence post-surgery.

ClinicalJune 24, 2026

Purinergic Activity in Extracellular Vesicles Linked to Melanoma Progression

Higher CD73 activity in total extracellular vesicles correlates with disease progression in melanoma patients.

ClinicalJune 20, 2026

MITF-Driven Plasticity in Melanoma: Key to Overcoming Therapy Resistance

MITF-dependent phenotype switching is identified as a central mechanism enabling melanoma cells to escape therapy.

ClinicalJune 19, 2026

Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study

A cross-cohort analysis identified 527 metagenome-assembled genomes associated with immunotherapy response in melanoma patients, including specific bacterial species linked to treatment outcomes.

ClinicalJune 17, 2026

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.

ClinicalJune 16, 2026

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

A Phase 2/3 study is evaluating CMP-001 in combination with nivolumab against nivolumab monotherapy in advanced melanoma.

ClinicalJune 16, 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death in high-risk melanoma patients.

ClinicalJune 14, 2026

New Biobank Established for Cutaneous Melanoma and Non-Melanoma Research

A new clinical trial is set up to create a biobank of human body material and clinical data from melanoma and non-melanoma patients.

ClinicalJune 12, 2026

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma

A first-in-human phase I/IIa trial is evaluating the safety and efficacy of [212Pb]VMT01, an alpha-particle therapy, in combination with nivolumab for advanced melanoma.

Companies

Assets

Recent signals(15)